Use of Febuxostat in Hyperuricemia Among Hemodialysis Patients

Benha University

Status: Completed

Conditions: Hemodialysis Complication; Hyperuricemia

Treatments: Drug: Febuxostat 40 milligramsTablet

Study type: Interventional

Funder types: Other; Industry

Identifiers

NCT03149939

BN-0316

Details and patient eligibility

About

Hyperuricemia is not infrequently encountered among hemodialysis patients. However, there is no clear data about use of febuxostat among hemodialysis patients, apart from very small case series. The aim of this study is to investigate the efficacy of using febuxostat for the treatment of Hyperuricemia among hemodialysis patients.

Enrollment: 19 patients

Sex: All

Ages: 19+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Age above 18 years
• Hemodialysis patient
• Hyperuricemia (Uric acid level above 6.0 mg/dL in females and 7.0 mg/dL in males)

Exclusion criteria

• Patient currently and/or recently received drugs for hyperuricemia within the last three months
• Patient had recent (within 3 months) change of erythropoiesis stimulating drugs or other drug known to increase uric acid e.g furosemide

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)